Glucose transporter expression in the human colon

Table 1 Criteria of inclusion for patients in each group

Patient group	Periodic Follow-up (n)	New stadiation of IBD (n)	Abdominal pain (n)	Chronic diarrhea (n)	Colorectal cancer screening (n)	Stipsis (n)	Hemorrhoids (n)
UC	16	2	-	-	-	-	-
CD	2	8	-	-	-	-	-
CTRL	31	-	5	4	2	1	1

¹Follow up after polypectomy. CD: Crohn‘s disease; UC: Ulcerative colitis; CTRL: Controls; IBD: Inflammatory bowel disease.

Table 2 Number of biopsies analyzed by immunohistochemistry in each tract of large intestine

Patient group	Biopsy status	Large			Intestine
		Proximal	Tract		Distal		Tract
		Cecum colon (n)	Ascending colon (n)	Transverse colon (n)	Descending colon (n)	Sigmoid colon (n)	Rectum (n)
UC	Inflamed	2	6	4	6	7	7
	Non-Inflamed	7	9	5	6	3	3
CD	Inflamed	0	4	3	4	4	4
	Non-Inflamed	1	1	0	1	2	1
CTRL	Inflamed	2	4	3	2	4	4
	Non-Inflamed	7	5	6	6	7	7

CD: Crohn‘s disease; UC: Ulcerative colitis; CTRL: Controls.

Table 3 Primary and secondary antibodies for immunohistochemical analysis

Antibody	Host	Dilution	Source
Anti-GLUT2	Goat	1:200	cat#ab111117, abcam, Cambridge, United Kingdom
Anti-GLUT5	Rabbit	1:400	cat#ab36057, abcam
Anti-SGLT1	Rabbit	1:200	cat#ab14686, abcam
Anti-LYVE-1	Rabbit	1:500	cat#Bs-1311R, Bioss,Woburn, MA, United States
Anti-VEGF	Rabbit	1:200	cat#RB-222, Thermo Scientific, Fremont, CA, United States
Polyclonal anti-rabbit IgG/biotinylated	Swine	1:400	cat#E0353, Dako, Milan, Italy
Polyclonal anti-goat IgG/biotinylated	Rabbit	1:400	cat#E0466, Dako
CyTM3-Fab fragment anti-rabbit IgG	Goat	1:100	cat#111-167, Jackson Lab., Baltimore, MD, United States
FITC-fab fragment anti-rabbit IgG	Goat	1:100	cat#111-097, Jackson Lab.
Unconjugated fab fragment anti-rabbit IgG	Goat	1:30	cat#111-007, Jackson Lab.

Table 4 Percentage of samples with GLUT2, SGLT1 and GLUT5 expression in epithelial cells of large intestine biopsies

Patient group	Large				Intestine
	Biopsy status	Proximal	Tract		Biopsy status	Distal	Tract
		GLUT2, %	SGLT1, %	GLUT5, %		GLUT2, %	SGLT1, %	GLUT5, %
UC	Inflamed (n = 12)	8	9	17	Inflamed (n = 20)	0	15	15
	Non-inflamed (n = 21)	5	5	33	Non-inflamed (n = 12)	8	8	17
CD	Inflamed (n = 7)	0	0	0	Inflamed (n = 12)	8	8	0
	Non-inflamed (n = 2)	0	0	0	Non-inflamed (n = 4)	0	0	0
CTRL	Inflamed (n = 9)	11	0	33	Inflamed (n = 10)	30	10	0
	Non-inflamed (n = 18)	17	0	17	Non-inflamed (n = 20)	20	1	15

CD: Crohn‘s disease; UC: Ulcerative colitis; CTRL: Controls.

Table 5 Percentage of samples with GLUT5 expression in clusters of lymphatic vessels in large intestine biopsies

Patient group	Large		Intestine
	Proximal	Tract	Distal	Tract
	Biopsy status	GLUT5, %	Biopsy status	GLUT5, %
UC	Inflamed (n = 12)	50.0	Inflamed (n = 20)	55.0
	Non-Inflamed (n = 21)	47.6	Non-Inflamed (n = 12)	83.3
CD	Inflamed (n = 7)	71.0	Inflamed (n = 12)	83.0
	Non-Inflamed (n = 2)	50.0	Non-Inflamed (n = 4)	25.0
CTRL	Inflamed (n = 9)	55.5	Inflamed (n = 10)	60.0
	Non-Inflamed (n = 18)	44.4	Non-Inflamed (n = 20)	85.0

CD: Crohn‘s disease; UC: Ulcerative colitis; CTRL: Controls.

Table 6 Percentage of samples with GLUT5-immunoreactive clusters of vessels in biopsy groups subdivided by patient body mass index

Patient group	Biopsy status	Large			Intestine
		Proximal	Tract		Distal	Tract
		Patient	BMI		Patient	BMI
		Normal weight, %	Over-weight, %	Obese, %	Normal weight, %	Over-weight, %	Obese, %
UC	Inflamed	71	20	0	70	43	33
	Non-inflamed	57	25	50	87	100	0
CD	Inflamed	80	50	0	87	75	0
	Non-inflamed	100	0	0	50	0	0
CTRL	Inflamed	80	25	0	67	50	0
	Non-inflamed	22	50	100	82	80	100

BMI: Body mass index; CD: Crohn‘s disease; UC: Ulcerative colitis; CTRL: Controls.